Evolent Health's (EVH) "Sell (E+)" Rating Reaffirmed at Weiss Ratings

Evolent Health (NYSE:EVH - Get Free Report)'s stock had its "sell (e+)" rating reiterated by equities researchers at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other research firms also recently weighed in on EVH. Stephens reissued an "equal weight" rating and issued a $9.00 price target on shares of Evolent Health in a research note on Wednesday, September 24th. BTIG Research reissued a "buy" rating and issued a $20.00 price target on shares of Evolent Health in a research note on Tuesday, September 30th. Truist Financial lifted their price target on Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Piper Sandler raised their price objective on Evolent Health from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Thursday, August 28th. Finally, JMP Securities restated a "market outperform" rating and issued a $13.00 price objective on shares of Evolent Health in a report on Friday, June 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $17.21.

Evolent Health Trading Down 0.9%

EVH stock opened at $8.05 on Wednesday. Evolent Health has a 1-year low of $7.06 and a 1-year high of $27.42. The firm has a market cap of $945.96 million, a P/E ratio of -5.00 and a beta of 0.66. The business's 50 day moving average is $9.08 and its 200-day moving average is $9.39. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.20). The company had revenue of $444.33 million during the quarter, compared to the consensus estimate of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The company's revenue for the quarter was down 31.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.30 earnings per share. Evolent Health has set its Q3 2025 guidance at EPS. Equities analysts anticipate that Evolent Health will post 0.08 earnings per share for the current fiscal year.

Institutional Trading of Evolent Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC grew its stake in shares of Evolent Health by 88.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company's stock worth $29,000 after buying an additional 1,194 shares during the last quarter. Banque Cantonale Vaudoise bought a new stake in shares of Evolent Health in the first quarter worth $25,000. Parallel Advisors LLC grew its stake in shares of Evolent Health by 82.6% in the second quarter. Parallel Advisors LLC now owns 3,487 shares of the technology company's stock worth $39,000 after purchasing an additional 1,577 shares during the last quarter. Strs Ohio bought a new stake in shares of Evolent Health in the first quarter worth $47,000. Finally, Headlands Technologies LLC bought a new stake in shares of Evolent Health in the second quarter worth $58,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.